» Articles » PMID: 29496087

Systemic Therapy for Colon Cancer

Overview
Date 2018 Mar 3
PMID 29496087
Citations 65
Authors
Affiliations
Soon will be listed here.
Abstract

Systemic treatments for patients with colon cancer has expanded broadly beyond 5-fluorouracil based chemotherapy. For early stage colon cancer patients who are considering adjuvant chemotherapy, multiple factors such as the risk of disease recurrence, absolute survival benefit of chemotherapy, treatment toxicity, and patient comorbid medical conditions must be taken into account. In the metastatic setting, biomarkers such as KRAS/NRAS/BRAF mutation, microsatellite instability status, and left- versus right-sided colon cancer have helped oncologists to tailor systemic treatment regimens, which include chemotherapy, targeted therapy, and immunotherapy.

Citing Articles

The prognostic importance of the negative regulators of ferroptosis, GPX4 and HSPB1, in patients with colorectal cancer.

Shimura T, Yin C, Ma R, Zhang A, Nagai Y, Shiratori A Oncol Lett. 2025; 29(3):144.

PMID: 39850719 PMC: 11755263. DOI: 10.3892/ol.2025.14890.


Multi-omics analysis of the biological function of the VEGF family in colon adenocarcinoma.

Yang J, Li C, Wang Z, Jiang K Funct Integr Genomics. 2024; 24(6):210.

PMID: 39527375 PMC: 11554882. DOI: 10.1007/s10142-024-01493-x.


Bicentric lesion of colon cancer with postoperative fever: A case report.

Wang M, Zao X, Ge Z, Fan X, Jin L, Zhang J Oncol Lett. 2024; 28(4):497.

PMID: 39211303 PMC: 11358718. DOI: 10.3892/ol.2024.14630.


Necroptosis induced by ruthenium (II) complexes as mitochondrial disruptors.

Goncalves J, Amaral J, Capela R, Perry M, Braga C, Gaspar M Cell Death Discov. 2024; 10(1):261.

PMID: 38806468 PMC: 11133381. DOI: 10.1038/s41420-024-02033-z.


Association between immune-related hub genes , and and colorectal cancer prognosis.

Wang L, Dong X, Yu M, Nie X, Du M, Zhao X Am J Transl Res. 2024; 16(1):216-223.

PMID: 38322560 PMC: 10839376.